Clinical Trial Detail

NCT ID NCT03056755
Title Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Alpelisib + Fulvestrant

Letrozole + BYL719

Age Groups: adult senior

Additional content available in CKB BOOST